Article
Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 1 Jul 2013
Burke Michael J, Wagner John E, Cao Qing, Ustun Celalettin, Verneris Michael R
Abstract excerpt
Despite remission rates of approximately 85% for children diagnosed with acute myeloid leukemia (AML), greater than 40% will die from relapsed disease. Patients with poor-risk molecular/cytogenetics and/or inadequate response to up-front therapy are typically considered high-risk (HR) and historically have poor outcomes with chemotherapy alone. We investigated whether allogeneic hematopoietic cell transplantation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
